Lycopene and gene expression in benign prostate: a phase II randomized trial

被引：1
|
作者：
Gann, Peter H. [1 ]
Dai, Yang [1 ]
Giangreco, Angeline Antonio [1 ]
Deaton, Ryan [1 ]
van Breemen, Richard [1 ]
Lu, Yi [1 ]
Rueter, Erika Enk [1 ]
Nonn, Larisa [1 ]
机构：
[1] Univ Illinois, Chicago, IL USA
来源：
CANCER RESEARCH | 2012年 / 72卷
关键词：
D O I：
10.1158/1538-7445.AM2012-LB-217
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
LB-217
引用
收藏
页数：1
相关论文
共 50 条
  • [41] A phase I trial of docetaxel combined with synthetic lycopene in subjects with metastatic prostate cancer.
    Lilly, Michael B.
    Ma, Chongze
    Yuan, Ying
    Chen, Wen-Pin
    Soloff, Adam C.
    McLaren, Christine E.
    Zi, Xiaolin
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [42] Differential gene expression analysis of a phase II randomized clinical trial of patients with endometrial cancer (EC) treated with megestrol acetate ± pterostilbene
    Dellinger, Thanh Hue
    Wu, Xiwei
    Cho, Hyejin
    Yost, Susan Elaine
    Ruel, Nora H.
    Invernizzi, Marta
    Senguttuvan, Rosemary Noel
    Frankel, Paul Henry
    Kebria, Mehdi
    Han, Ernest Soyoung
    Song, Mihae
    De Leon, Maria
    Eng, Melissa
    Tinsley, Raechelle
    Schmolze, Daniel
    Chang, Sue
    Stella, Javier Arias
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [43] Characteristic gene expression profiles of benign prostatic hypertrophy and prostate cancer
    Endo, Takumi
    Uzawa, Katsuhiro
    Suzuki, Hiroyoshi
    Tanzawa, Hideki
    Ichikawa, Tomohiko
    INTERNATIONAL JOURNAL OF ONCOLOGY, 2009, 35 (03) : 499 - 509
  • [44] Epithelium/stroma related gene expression profiles in benign prostate hyperplasia
    Matsui, H
    Suzuki, K
    Hasumi, M
    Koike, H
    Okugi, H
    Nakazato, H
    Shibata, Y
    Ito, K
    Yamanaka, H
    JOURNAL OF UROLOGY, 2003, 169 (04): : 283 - 283
  • [45] Inhibition of prostate cell growth by BXL-628, a calcitriol analogue selected for a phase II clinical trial in patients with benign prostate hyperplasia
    Crescioli, C
    Ferruzzi, P
    Caporali, A
    Scaltriti, M
    Bettuzzi, S
    Mancina, R
    Gelmini, S
    Serio, M
    Villari, D
    Vannelli, GB
    Colli, E
    Adorini, L
    Maggi, M
    EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2004, 150 (04) : 591 - 603
  • [46] PROFILING GENE EXPRESSION IN A PHASE II PLASMODIUM VIVAX IRRADIATED SPOROZOITE VACCINE TRIAL
    Rojas-Pena, Monica L.
    Arafat, Dalia
    Arevalo-Herrera, Myriam
    Herrera, Socrates
    Vasquez, Juan M.
    Gibson, Greg
    AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE, 2017, 95 (05): : 588 - 589
  • [47] Lycopene for Advanced Hormone Refractory Prostate Cancer: A Prospective, Open Phase II Pilot Study
    Schwenke, Carla
    Ubrig, Burkhard
    Thuermann, Petra
    Eggersmann, Christian
    Roth, Stephan
    JOURNAL OF UROLOGY, 2009, 181 (03): : 1098 - 1103
  • [48] Early selection in a randomized phase II clinical trial
    Steinberg, SM
    Venzon, DJ
    STATISTICS IN MEDICINE, 2002, 21 (12) : 1711 - 1726
  • [49] Randomized, adaptive, phase II selection trial of four chemotherapy regimens in androgen independent prostate cancer (AIPC).
    Millikan, RE
    Thall, P
    Pagliaro, L
    Williams, D
    Brown, M
    Logothetis, C
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 397S - 397S
  • [50] Prospective randomized phase II trial of pegylated doxorubicin in the management of symptomatic hormone-refractory prostate carcinoma
    Heidenreich, A
    Sommer, F
    Ohimann, CH
    Schrader, AJ
    Olbert, P
    Goecke, J
    Engelmann, UH
    CANCER, 2004, 101 (05) : 948 - 956
12345